Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: Results from two double-blind, placebo-controlled studies

Diabetes, Obesity and Metabolism

Volumn 7, Issue 1, 2005, Pages 28-39

  Fujioka, Ken ^a   Brazg, R L ^b   Raz, I ^c   Bruce, S ^d   Joyal, S ^d   Swanink, R ^e   Pans, M ^e  

^a SCRIPPS CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Hadassah Diabetes Center   (Israel)

^d BRISTOL MYERS SQUIBB   (United States)

^e BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Metformin; Oral antidiabetic therapy; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY WEIGHT; BONE PAIN; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DYSPEPSIA; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HEARTBURN; HUMAN; HYPERTENSION; INFLUENZA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 12744273484     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00369.x     Document Type: Article

References (21)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
2. Paes AHP, Bakker A, Soe-Agnie S-J. Impact of dosage frequency on patient compliance. Diabetes Care 1997; 20: 1512-1517.
3. Reasner C, Göke B. Overcoming the barriers to effective glycaemic control for type 2 diabetes. Br J Diab Vasc Dis 2002; 2: 290-295.
4. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460-467.
5. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-241.
6. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-749.
7. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.
8. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab 1991; 17: 224-231.
9. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999; 20: 489-503.
10. Gusler G, Gorsline J, Levy G et al.. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers J Clin Pharmacol 2001; 41: 655-661.
11. Fujioka K, Joyal S, Bruce S. Type 2 diabetes patients switched from immediate-release metformin bid to an extended-release qd formulation in a randomized, controlled trial maintain comparable glycemic control. Clin Ther 2003; 25: 515-529.
12. Marathe P, Turner K. Steady-state pharmacokinetics of the metformin extended-release tablet versus immediate-release metformin in healthy subjects. Diabetes 2002; 51: (Suppl. 2): A474.
13. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis 2001; 1: 28-36.
14. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
15. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002; 4: 201-208.
16. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995; 11 (Suppl. 1): S57-S62.
17. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991; 14: 342-344.
18. Rains SG, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 1988; 5: 653-658.
19. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001; 23: 1311-1320.
20. Morris AD, Brennan GM, MacDonald TM, Donnan PT. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000; 49 (Suppl. 1): A76.
21. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM. The development of polypharmacy. A longitudinal study. Fam Pract 2000; 17: 261-267.